QRGenetics

Developer of an AI-based drug discovery engine for personalized drug repurposing services for rare diseases.

Health Tech & Life Sciences
Active
Pre-Funding Tel Aviv-Yafo, Israel Founded 2019
Last updated 2026-07-20
Total raised
Last: Grant 2023-12
Stage
Pre-Funding
Founded
2019
Headcount
5
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

QRGenetics is a provider of personalized drug repurposing services for rare diseases. The company utilizes patients' genetic data to confirm disease mutation with molecular and clinical status, employing computational and biological modeling technologies for personalized drug repurposing. They also offer cell-level prognosis and decision support tools to physicians. Their AI-supported drug discovery engine uses exclusive spatial analytics and proprietary datasets to rapidly identify novel drug-target combinations, aiming to find new treatments for individual patients with rare diseases and expand indications for common genetic diseases.

Funding history · 1 round · — total

2023-11
Grant Undisclosed

Headcount over time

From 4 (2020-02) to 8 (2025-10) · +4 (+100%) · 16 points · source: Finder history + radar grounding
90 2020-02 2025-10

Q&A

What is QRGenetics' primary focus?
QRGenetics is developing an AI-supported drug discovery engine to identify potential therapies for common genetic diseases by finding new treatments for patients with similar rare-disease mutations.
When was QRGenetics founded?
QRGenetics was founded in June 2019.
How many employees does QRGenetics currently have?
QRGenetics has 1-10 employees.
Who are the co-founders of QRGenetics?
The co-founders of QRGenetics are Shane Wald-Altman, Dan Lavi, and Miguel Weil.
What type of funding did QRGenetics receive in December 2023?
In December 2023, QRGenetics received a Grant, with Israel Investment Partners (IIP) listed as an investor.
What is QRGenetics' current funding stage?
QRGenetics is currently in the Pre-Funding stage.
In which sector does QRGenetics primarily operate?
QRGenetics' primary sector is Health Tech & Life Sciences.
What technologies does QRGenetics utilize in its drug discovery engine?
QRGenetics utilizes Artificial Intelligence, Deep Learning, Machine Learning, Biologicals, and Genes in its drug discovery engine.

Team · 5

Shane Wald Altman
Founder · Co-Founder & CEO
Miguel Weil
Founder · Co-Founder & Scientific Advisor
Dan Lavi
Founder · Co-Founder
Ido Gonen
Founder · Co-Founder
Oren Shuster
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceDeep LearningMachine LearningBiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2B2C

Highlights

1 PatentsVerified

Tags

patientsdeep-learninggenetic-disordersdiagnosticspharma-companiesdrug-discoverycardiovasculartreatmentsdecision-supportautomationrare-diseasesgeneticsdigital-healthcaretherapeuticspersonalizationartificial-intelligencepharmaceuticalsmachine-learningbiotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteqrgenetics.com
LinkedInlinkedin.com/company/30769932

Identifiers & details

Legal nameQR Genetics Ltd.
Founded2019-6
Employees (exact)5

Radar intelligence

Patents

EPO2

Web history (Wayback)

Domainqrgenetics.com

Certificate / subdomain footprint

Subdomains6

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516018769
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2019-05-02
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens0
Registry events0
Registered addressירדן 23 רמת השרון